版本:
中国

BRIEF-Delmar Pharmaceuticals announces Q3 loss per share $0.18

May 18 Delmar Pharmaceuticals Inc

* Delmar Pharmaceuticals announces third quarter fiscal year 2017 financial results

* Q3 loss per share $0.18

* Delmar Pharmaceuticals Inc - Recent financing enables co to remain on-track to initiate pivotal phase 3 clinical trial of VAL-083 in refractory GBM

* Delmar Pharma - Current working capital, including proceeds from recent financing is sufficient to support planned operations for next 18-24 months Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐